H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses. - Wikidata - wikimedia - TriplyDB

H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses.

H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses.

http://www.wikidata.org/entity/Q35094040

about

Long-Term Safety and Immunogenicity of a Tetravalent Live-Attenuated Dengue Vaccine and Evaluation of a Booster Dose Administered to Healthy Thai Children H5N1 vaccines in humans Advances in aluminum hydroxide-based adjuvant research and its mechanism Administration of AS03B-adjuvanted A(H1N1)pdm09 vaccine in children aged <3 years enhances antibody response to H3 and B viruses following a single dose of trivalent vaccine one year later.Long-term booster schedules with AS03A-adjuvanted heterologous H5N1 vaccines induces rapid and broad immune responses in Asian adults.Heterologous prime-boost vaccination with MF59-adjuvanted H5 vaccines promotes antibody affinity maturation towards the hemagglutinin HA1 domain and broad H5N1 cross-clade neutralization History of narcolepsy at Stanford University.Responses to A(H1N1)pdm09 influenza vaccines in participants previously vaccinated with seasonal influenza vaccine: a randomized, observer-blind, controlled study.Considerations for the rapid deployment of vaccines against H7N9 influenza.Influenza vaccines: a moving interdisciplinary field.Matrix M(TM) adjuvanted virosomal H5N1 vaccine induces balanced Th1/Th2 CD4(+) T cell responses in man.Antigenic differences between AS03 adjuvanted influenza A (H1N1) pandemic vaccines: implications for pandemrix-associated narcolepsy risk.Oral priming with replicating adenovirus serotype 4 followed by subunit H5N1 vaccine boost promotes antibody affinity maturation and expands H5N1 cross-clade neutralization.Phase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years: follow-up of safety and immunogenicity persistence at 24 months post-vaccination.AS03-Adjuvanted, Very-Low-Dose Influenza Vaccines Induce Distinctive Immune Responses Compared to Unadjuvanted High-Dose Vaccines in BALB/c Mice.Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studies Refining the approach to vaccines against influenza A viruses with pandemic potential.Antibody Persistence in Adults Two Years after Vaccination with an H1N1 2009 Pandemic Influenza Virus-Like Particle Vaccine.A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines.Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials.Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion.An assessment of prime-boost vaccination schedules with AS03A -adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults.The human potential of a recombinant pandemic influenza vaccine produced in tobacco plants.Adjuvant solution for pandemic influenza vaccine production Unusual patterns of IgG avidity in some young children following two doses of the adjuvanted pandemic H1N1 (2009) influenza virus vaccine.Long-term persistence of humoral and cellular immune responses induced by an AS03A-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized study in adults aged 18-60 years and older.Memory CD4 T cell-mediated immunity against influenza A virus: more than a little helpful.Superior antigen-specific CD4+ T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older.Vaccine Potentiation by Combination Adjuvants Immunosenescence and Challenges of Vaccination against Influenza in the Aging Population.Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: follow-up through Month 48 in a Phase III randomized study.Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03B adjuvant: Results of a randomized phase I trial.Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years.Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines: randomized, double-blind study in malaria-naïve adults A randomized, controlled dose-finding Phase II study of the M72/AS01 candidate tuberculosis vaccine in healthy PPD-positive adults.Safety, immunogenicity, and antibody persistence following an investigational Streptococcus pneumoniae and Haemophilus influenzae triple-protein vaccine in a phase 1 randomized controlled study in healthy adults.Improving immunogenicity and effectiveness of influenza vaccine in older adults.Influenza vaccines: T-cell responses deserve more attention.Immunological assessment of influenza vaccines and immune correlates of protection.

P2860

Q26314710-27F4DD2D-1C92-4013-A88D-3586C5C70615 Q27000896-6A00BC46-2CAC-4ECF-9AA0-125AAE07E2CF Q27007659-DE8BB154-E02D-4216-869C-9D8BA7DA0C4A Q30354814-BE78E700-CCD9-43FD-9F8F-69D6C6815045 Q30360190-9DF870AB-52FF-4D93-B347-AE12DC2A211E Q30361644-ED17C45A-DE55-411B-A79E-EFA848067CF7 Q30362536-D1C44EFF-8F4A-4875-AC5C-A209A415106A Q30362883-14A2E84D-C003-44EF-A76B-7C577C536B14 Q30364635-8D77BD94-FE58-4374-AFB9-C7A911D8A46C Q30367695-9DF10E7D-594C-4135-999C-3C432A53A3F7 Q30368937-3CA4EB8F-7F3A-4880-AFAA-B49484B2AAFA Q30369654-793B2922-BD67-4469-A74A-7076200AC33F Q30371162-68833E24-2C7E-4B37-B0F2-7C1BC901DF41 Q30371445-30458AE1-CDC4-4BDD-AEE2-8BAE351E91AA Q30374665-FBE2C494-8511-4C33-AE15-FFCA90D3A559 Q30376727-DDFC012A-5260-439D-A9C1-7C129CE718A0 Q30381595-679534D8-2FCB-4DBD-B69D-662C363A98BF Q30384943-98CE4CBE-852F-4963-9FB1-EA2D14AAF7EE Q30401247-744E2F9E-E077-4D45-B847-96D20BEF6581 Q30401398-A80B59FA-8EBC-4828-9B8D-35B830B5BAB2 Q30413695-D3E3C9B9-9D37-4D6C-891A-3CB5C21BD3CE Q30414122-E730CE44-42C0-4C5F-8274-E9422F1DDE84 Q30417273-5BE25AC8-94C6-4F66-B0DF-3013251A2937 Q30422038-60D3601C-55A7-4A52-98C6-ABC65976903F Q30426236-3E772826-DC97-45CD-BB91-C9631F4E8746 Q30429185-77523984-5496-4DBC-A5CF-8839FA867E41 Q30431078-DC064A6B-CDD1-430E-B73A-CF18869B3CE8 Q34067461-106096C3-C80E-49E4-A468-653CBA7EC109 Q35826767-184EBABC-D878-4468-A1D2-115D9AD08F2A Q35874111-543DC1B9-1751-4503-A663-E99C9E06E475 Q35886612-BDDDC862-2B9F-48ED-845B-1732C3AC64BD Q35886910-A3ADD4BB-6CA7-4187-85AC-9746E6F6A213 Q35887417-0DD540CF-F6FE-4DB0-B184-0FA3C9293C58 Q35918838-29F06394-5EF6-47BD-B48E-745F0886847C Q36978351-E7147EC9-0635-431A-9FA4-C1B244572518 Q37301506-BCE3EDE4-7799-49A4-8F8A-3CA29E429CF0 Q37544974-443101E9-339E-43D2-A168-94AFC35F9D33 Q37951523-FBA5898A-579C-4A13-AF2A-1F53A493AB27 Q38045918-218FC997-7A96-4496-93CF-647EDEDA93F5 Q38105339-3686AA21-9868-4646-97E5-4AD32188EFD7

P2860

H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses.

http://www.wikidata.org/entity/Q35094040

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

H5N1 influenza vaccine formula ...... nctional CD4 T-cell responses.

@ast

H5N1 influenza vaccine formula ...... nctional CD4 T-cell responses.

@en

type

label

H5N1 influenza vaccine formula ...... nctional CD4 T-cell responses.

@ast

H5N1 influenza vaccine formula ...... nctional CD4 T-cell responses.

@en

prefLabel

H5N1 influenza vaccine formula ...... nctional CD4 T-cell responses.

@ast

H5N1 influenza vaccine formula ...... nctional CD4 T-cell responses.

@en

P1433

Q35094040-6AD1A1EA-07C4-4A51-A14C-77C252703DBD

P1476

Q35094040-2F003E00-F650-4909-84AB-4CD48DF0C5BF

P2093

Q35094040-1565F43C-1C6B-4FEA-B3F6-E554BAEF05BB

Q35094040-3FA4DEAB-F428-4BB1-9160-D87D6A190DF1

Q35094040-41EA621B-E156-441D-A291-B5804FD622D7

Q35094040-63051DF9-4806-46BF-9A9A-8F0778C5FF82

Q35094040-87F4A1D0-F9D5-4781-8587-4961885E11CE

Q35094040-B3B43BB9-6CD2-4AD4-BCE2-332DDF3EE1B8

Q35094040-DA09A7A6-3F9B-4A5D-B101-7FDAF817B02A

P2860

Q35094040-0845A25D-3DCB-4D3A-B43E-3C5F3C79852E

Q35094040-1A69FE21-AB53-44DF-8A3B-01F514CAB62D

Q35094040-1C7C95FB-698B-4AC5-8BA4-D5067F761409

Q35094040-2504CEA5-8506-402B-8F8F-5A8FC29E2FCD

Q35094040-2BF3C71F-F1C9-4003-9BE4-CCA73347DB78

Q35094040-4A4D6A72-7635-44FD-8B78-4BC6FA6BEEE8

Q35094040-4BF3C50A-387C-4FA1-BF27-C3462A0C11FC

Q35094040-4C2C646F-C3BD-4BB3-A528-6ECAEF23777A

Q35094040-535D5896-87C0-4A64-8165-E1936235DD86

Q35094040-56CBE48D-0C4F-4E79-A0CC-AF8265FC1B75

P2888

Q35094040-979F44EB-648A-4DF7-9969-8BE953BC92FA

P304

Q35094040-2AF71A04-1D0E-4D1B-8C7B-EA6130D55C29

P31

Q35094040-87D01660-545F-492C-8FF9-A90180CA9BAA

P356

Q35094040-2BE28C46-49EB-49A5-904B-BD2C77D26C67

P433

Q35094040-EBAD6755-E9AC-42DB-A3E6-107F8806FF68

P478

Q35094040-4AC7619A-8498-4013-BF48-5C0DB1161C2B

P50

Q35094040-73B2A221-37D9-4772-89FD-5C81339D1D69

P577

Q35094040-45435346-5C36-491F-8E84-603FC250F508

P5875

Q35094040-55A3BC4D-A906-4B7D-80A1-D07FF81A8A60

P698

Q35094040-9DBDC059-B9A3-460A-9C51-EFEB21DED77D

P932

Q35094040-228E2CAC-475C-42F3-9ADC-617520571876

P356

S10875-010-9490-6

P1433

Journal of Clinical Immunology

P1476

H5N1 influenza vaccine formula ...... unctional CD4 T-cell responses

@en

P2093

Emmanuel Hanon

http://www.w3.org/2001/XMLSchema#string

Geert G Leroux-Roels

http://www.w3.org/2001/XMLSchema#string

Isabel Leroux-Roels

http://www.w3.org/2001/XMLSchema#string

Mamadou Dramé

http://www.w3.org/2001/XMLSchema#string

Marcelle Van Mechelen

http://www.w3.org/2001/XMLSchema#string

Philippe Moris

http://www.w3.org/2001/XMLSchema#string

Robbert van der Most

http://www.w3.org/2001/XMLSchema#string

P2860

Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine

Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages

Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals

Central memory and effector memory T cell subsets: function, generation, and maintenance

Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine

Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines.

Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system.

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial.

An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.

P2888

s10875-010-9490-6

P304

443-454

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10875-010-9490-6

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

Frédéric Clement

P577

2010-12-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49698518

http://www.w3.org/2001/XMLSchema#string

P698

21174144

http://www.w3.org/2001/XMLSchema#string

P932

3132412

http://www.w3.org/2001/XMLSchema#string